We have shown that PPARγ inhibition by the investigational antagonist GW9662, either alone or in combinationwith troglitazone, does not affect rat F98 glioma cell invasiveness in a Boydenchamber assay, suggesting that the effects observed are not mediated by PPARγ [9]. The gene discussed is PPARG; the disease is central nervous system cancer.